Cargando…
Outcomes of COVID-19 in an Advanced Heart Failure Practice: A Single Center Study
PURPOSE: Patients with heart failure (HF) carry an increased risk of mortality and morbidity with COVID-19. The objective of this study is to compare the outcomes of HF (stage C or D), Left Ventricular Assist Device (LVAD) or Heart Transplant (HTx) patients who were diagnosed with COVID-19. METHODS:...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Published by Elsevier Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8988652/ http://dx.doi.org/10.1016/j.healun.2022.01.418 |
_version_ | 1784683010259419136 |
---|---|
author | Cunningham, L.C. George, S. Nelson, D. Horstmanshof, D.A. Long, J.W. Banayosy, A.M. El |
author_facet | Cunningham, L.C. George, S. Nelson, D. Horstmanshof, D.A. Long, J.W. Banayosy, A.M. El |
author_sort | Cunningham, L.C. |
collection | PubMed |
description | PURPOSE: Patients with heart failure (HF) carry an increased risk of mortality and morbidity with COVID-19. The objective of this study is to compare the outcomes of HF (stage C or D), Left Ventricular Assist Device (LVAD) or Heart Transplant (HTx) patients who were diagnosed with COVID-19. METHODS: Out of 2635 patients followed in our program (HF=2234, LVAD=167, HTx=234), 96 patients diagnosed with COVID-19 infection between March 2020 to January 2021 were included in this study. Hospital length of stay (LOS), requirement for mechanical ventilation, and mortality rate were compared. Kaplan-Meier analysis was used to compare survival. RESULTS: The distribution of COVID among the 96 patients was: HTx = 15.8%, LVAD = 9.6% and HF = 1.9%. Table 1 outlines the clinical characteristics and outcomes of the 3 cohorts. A total of 49 patients were hospitalized: 18 (41.9%) HF, 8 (50%) LVAD, and 23 (62.2%) HTx. Of the hospitalized patients, 5 (27.8%) required ICU care in the HF, 2 (25%) LVAD, and 6 (26.1%) HTx groups. The median ICU LOS was significantly higher in HTx (24 days, p=0.04) when compared to HF (10 days) group. HTx patients had the highest 180-day mortality, followed by LVAD, and then HF patients (18.9%, 12.5% and 11.6%, respectively). All deaths occurred within 50 days from diagnosis. Among LVAD patients, COPD was the highest predictor of mortality (69% prevalence). CONCLUSION: This report is among the first to describe the impact of COVID-19 on a comprehensive advanced heart failure (HF) practice. Our data highlights the risks of morbidity and mortality faced by HF and immunocompromised patients with COVID-19 infection. A mortality rate of 19% with HTx patients acquiring COVID is ominous (even if better than reported rates of 25%). Likewise, though not as high, mortality rates for COVID infected advanced HF and LVAD patients of 12% each represent substantial risk. Protecting these patients with all possible preventative and therapeutic options is an essential imperative. |
format | Online Article Text |
id | pubmed-8988652 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Published by Elsevier Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-89886522022-04-11 Outcomes of COVID-19 in an Advanced Heart Failure Practice: A Single Center Study Cunningham, L.C. George, S. Nelson, D. Horstmanshof, D.A. Long, J.W. Banayosy, A.M. El J Heart Lung Transplant (397) PURPOSE: Patients with heart failure (HF) carry an increased risk of mortality and morbidity with COVID-19. The objective of this study is to compare the outcomes of HF (stage C or D), Left Ventricular Assist Device (LVAD) or Heart Transplant (HTx) patients who were diagnosed with COVID-19. METHODS: Out of 2635 patients followed in our program (HF=2234, LVAD=167, HTx=234), 96 patients diagnosed with COVID-19 infection between March 2020 to January 2021 were included in this study. Hospital length of stay (LOS), requirement for mechanical ventilation, and mortality rate were compared. Kaplan-Meier analysis was used to compare survival. RESULTS: The distribution of COVID among the 96 patients was: HTx = 15.8%, LVAD = 9.6% and HF = 1.9%. Table 1 outlines the clinical characteristics and outcomes of the 3 cohorts. A total of 49 patients were hospitalized: 18 (41.9%) HF, 8 (50%) LVAD, and 23 (62.2%) HTx. Of the hospitalized patients, 5 (27.8%) required ICU care in the HF, 2 (25%) LVAD, and 6 (26.1%) HTx groups. The median ICU LOS was significantly higher in HTx (24 days, p=0.04) when compared to HF (10 days) group. HTx patients had the highest 180-day mortality, followed by LVAD, and then HF patients (18.9%, 12.5% and 11.6%, respectively). All deaths occurred within 50 days from diagnosis. Among LVAD patients, COPD was the highest predictor of mortality (69% prevalence). CONCLUSION: This report is among the first to describe the impact of COVID-19 on a comprehensive advanced heart failure (HF) practice. Our data highlights the risks of morbidity and mortality faced by HF and immunocompromised patients with COVID-19 infection. A mortality rate of 19% with HTx patients acquiring COVID is ominous (even if better than reported rates of 25%). Likewise, though not as high, mortality rates for COVID infected advanced HF and LVAD patients of 12% each represent substantial risk. Protecting these patients with all possible preventative and therapeutic options is an essential imperative. Published by Elsevier Inc. 2022-04 2022-04-07 /pmc/articles/PMC8988652/ http://dx.doi.org/10.1016/j.healun.2022.01.418 Text en Copyright © 2022 Published by Elsevier Inc. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | (397) Cunningham, L.C. George, S. Nelson, D. Horstmanshof, D.A. Long, J.W. Banayosy, A.M. El Outcomes of COVID-19 in an Advanced Heart Failure Practice: A Single Center Study |
title | Outcomes of COVID-19 in an Advanced Heart Failure Practice: A Single Center Study |
title_full | Outcomes of COVID-19 in an Advanced Heart Failure Practice: A Single Center Study |
title_fullStr | Outcomes of COVID-19 in an Advanced Heart Failure Practice: A Single Center Study |
title_full_unstemmed | Outcomes of COVID-19 in an Advanced Heart Failure Practice: A Single Center Study |
title_short | Outcomes of COVID-19 in an Advanced Heart Failure Practice: A Single Center Study |
title_sort | outcomes of covid-19 in an advanced heart failure practice: a single center study |
topic | (397) |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8988652/ http://dx.doi.org/10.1016/j.healun.2022.01.418 |
work_keys_str_mv | AT cunninghamlc outcomesofcovid19inanadvancedheartfailurepracticeasinglecenterstudy AT georges outcomesofcovid19inanadvancedheartfailurepracticeasinglecenterstudy AT nelsond outcomesofcovid19inanadvancedheartfailurepracticeasinglecenterstudy AT horstmanshofda outcomesofcovid19inanadvancedheartfailurepracticeasinglecenterstudy AT longjw outcomesofcovid19inanadvancedheartfailurepracticeasinglecenterstudy AT banayosyamel outcomesofcovid19inanadvancedheartfailurepracticeasinglecenterstudy |